Quantcast
Last updated on April 17, 2014 at 13:30 EDT

Latest Pharmacogenetics Stories

2009-10-30 10:24:00

LONDON, October 30 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has entered an intensive partnering programme following on from its successful pharmacogenetic conference in September(1). The meeting recognised that while pharmacogenetics and genetics have great potential in helping the biopharmaceutical industry overcome its many challenges, early clinical collaboration between companies, academia, regulators...

2009-10-26 15:14:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Pharmacogenomics: Delivering on the Promise http://www.reportlinker.com/p0156560/Reportlinker-Adds-Pharmacogenomics-Delivering-on-the-Promise.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Pharmacogenomics (PGx) is often considered "the great new wave" in medicine, promising better, safer, and more affordable healthcare....

2009-10-22 07:45:00

CINCINNATI, Oct. 22 /PRNewswire/ -- AssureRx, a personalized medicine company, announced today that it has begun a full launch of its first product, GeneSightRx(TM) This lab-developed, pharmacogenetic test had previously been commercially available only on a limited basis. The test combines state-of-the-art genetic testing technology with a multi-variate, algorithmic, interpretive report to help guide physicians during their decision-making process before prescribing psychiatric...

2009-09-18 10:05:00

LONDON, September 18 /PRNewswire/ -- London Genetics Limited, which expedites pharmacogenetic partnerships between the biopharmaceutical industry and London-based centres of excellence in genetics research, announces today several prestigious appointments to its Board and management team. The new appointments, which include Dr Barrie Ward as Chairman, will drive the next phase of the company's growth as the importance of pharmacogenetics in drug development increases. They bring important...

2009-08-26 14:14:00

A gene variant carried by about one-third of the population plays a major role in how they respond to an anti-clotting medicine, U.S. researchers said. Rochelle M. Long, director of the National Institutes of Health Pharmacogenetics Research Network, said people with the variant produce a defective version of the CYP2C19 enzyme and are less able to activate the drug clopidogrel, also known as Plavix. Long said Plavix, one of the world's best-selling medicines, prevents blood clots in...

2009-06-09 08:00:00

Experienced Executive to Lead Personalized Medicine Company in Next Phase of Growth CINCINNATI, June 9 /PRNewswire/ -- AssureRx, a personalized medicine company, announced today that James S. Burns has joined the Mason-based company as its new President and CEO. Burns comes to AssureRx with more than 30 years of executive experience in the strategic management of science and technology for pharmaceutical, diagnostic, and biotech companies. Most recently, he was president and CEO of...

2009-06-01 07:14:22

 The International Serious Adverse Events Consortium (SAEC) announced today initial results from its research designed to discover genetic markers that may predict individuals at risk for serious drug induced liver injury (DILI). The SAEC is a nonprofit research corporation, launched in the fall of 2007, comprised of and funded by 10 leading pharmaceutical companies and the Wellcome Trust. The U.S. Food and Drug Administration (FDA) also contributes to the scientific and strategic...

2009-02-18 08:00:00

Study Suggests Genetic Approach to Personalized Screening of Anti-Rejection Drug Dosing CINCINNATI, Feb. 18 /PRNewswire-USNewswire/ -- Screening for mutations in a gene that helps the body metabolize a kidney transplant anti-rejection drug may predict which children are at higher risk for side effects, including compromised white blood cell count or organ rejection, according to new research. Published online Feb. 18 by the Nature journal Clinical Pharmacology and Therapeutics, the study...

2009-01-22 06:00:00

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent, Plavix. Plavix, commonly known as Clopidogrel, is an anti-platelet agent used in the treatment for coronary artery disease, peripheral vascular disease and cerebrovascular disease. To realize the...

2009-01-14 05:11:00

LONDON, Jan. 14 /PRNewswire/ -- The pharmaceutical industry is currently facing some key challenges. The increase in drug development costs, a decrease in the number of drugs being approved, and scrutiny from regulatory authorities are forcing companies to look at alternative revenue generators. Patients themselves are also demanding more effective and safer drugs. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) Pharmacogenomics therefore presents a convincing alternative to...